Valneva SE (VALN) Cash from Financing Activities (2021 - 2026)
Valneva SE (VALN) posted quarterly Cash from Financing Activities of -$5.3 million for Q1 2026, up 16.0% year-on-year from -$4.6 million in Q1 2025, and up 49.93% on a QoQ basis from -$10.7 million in Q4 2025.
Valneva SE (VALN) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Cash from Financing Activities for 6 consecutive years, with -$5.3 million the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities rose 16.0% year-over-year to -$5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $309523.6 (down 99.16% YoY) and the FY2025 annual result came in at -$706669.6, down 102.02% from the prior year.
- Cash from Financing Activities grew to -$5.3 million in Q1 2026 per VALN's latest filing, from -$10.7 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for VALN reached as high as $10.8 billion in Q3 2023 and fell as low as -$10.8 billion in Q2 2023.
- A 5-year average of $20.3 million and a median of -$632702.6 in 2025 frame the typical range for Cash from Financing Activities.
- The largest YoY upside for Cash from Financing Activities was 57059.15% in 2023 against a maximum downside of 9205.77% in 2023.
- Year by year, Cash from Financing Activities stood at $106.4 million in 2022, then tumbled by 60.48% to $42.0 million in 2023, then slumped by 112.42% to -$5.2 million in 2024, then sank by 104.01% to -$10.7 million in 2025, then jumped by 49.93% to -$5.3 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$5.3 million, -$10.7 million, and -$632702.6 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -5.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.34 Mn |
| Mar 31, 2026 | -5.34 Mn |
| Dec 31, 2025 | -10.66 Mn |
| Dec 31, 2025 | -10.66 Mn |
| Sep 30, 2025 | -632,702.57 |
| Sep 30, 2025 | -632,702.57 |
| Jun 30, 2025 | 16.93 Mn |
| Jun 30, 2025 | 16.93 Mn |
| Mar 31, 2025 | -6.35 Mn |
| Mar 31, 2025 | -6.35 Mn |
| Dec 31, 2024 | -5.22 Mn |
| Dec 31, 2024 | -5.22 Mn |
| Sep 30, 2024 | 59.02 Mn |
| Sep 30, 2024 | 59.02 Mn |
| Jun 30, 2024 | -10.39 Mn |
| Jun 30, 2024 | -10.39 Mn |
| Mar 31, 2024 | -8.49 Mn |
| Mar 31, 2024 | -8.49 Mn |
| Dec 31, 2023 | 42.04 Mn |
| Dec 31, 2023 | 42.04 Mn |